Cambridge Investment Research Advisors
SLS icon

Cambridge Investment Research Advisors’s SELLAS Life Sciences SLS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
16,163
+3,728
+30% +$25.7K ﹤0.01% 3655
2026
Q1 		$53K Hold
12,435
– – ﹤0.01% 3856
2025
Q4 		$47K Sell
12,435
-7,565
-38% -$14.7K ﹤0.01% 3759
2025
Q3 		$32K Buy
+20,000
New +$35.6K ﹤0.01% 3677

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cambridge Investment Research Advisors's SLS Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its SELLAS Life Sciences (SLS) stake by 30% in Q2 2026, buying an estimated $25.7K and bringing the position to 16,163 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Cambridge Investment Research Advisors first reported a position in SLS in Q3 2025 and has held it in 4 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Cambridge Investment Research Advisors held 16,163 shares of SELLAS Life Sciences worth $239K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 3,728 SELLAS Life Sciences shares in Q2 2026, an estimated $25.7K.
  • SELLAS Life Sciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3655 holding.
  • Cambridge Investment Research Advisors first reported a position in SELLAS Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.